In summary, we performed microarray gene expression analysis on hematological malignancies of different origins, healthy hematopoietic cells and various (IFN-γ pre-treated) non-hematopoietic cell types and demonstrate that our microarray gene expression database allows detailed analysis and selection of candidate targets with hematopoietic (lineage-)restricted expression for immunotherapy of hematological cancers. This evidence concerns the gene IFNG and hematologic disorder.